Heyholder
‹ Activism Filings

SAMIL PHARMACEUTICAL CO.,LTD CEO group extends share-backed loan, pledged shares at 3.16%

SAMIL PHARMACEUTICAL CO.,LTD· Report on Large Shareholdings

AI summary · Not investment advice

The stake of the CEO and 13 related parties in SAMIL PHARMACEUTICAL CO.,LTD was unchanged at 25.96%, while pledged shares fell from 797,392 to 686,203.

Total under contracts

686,203 shares

Previous 3.68% → now 3.16%

Key facts

Stake
25.96%Same as previous
Reporting holder
The CEO and 13 related parties
Purpose of holding
To influence management
Relationship with issuer
Registered executive
Report type
Amendment
Reason for report
Extension of a share-backed loan by a related party
Shares held
5,630,509 sharesSame as previous
Reason for amendment
Extension of a share-backed loan by a related party
Previous shares under major contracts
797,392 shares
Shares under major contracts
686,203 shares
Reporting obligation date
Oct 6, 2026

Commentary

AI commentary · Not investment advice

What happened

The CEO of SAMIL PHARMACEUTICAL and 13 related parties filed an amended report because the terms of their share-backed loans changed. A related party's loan from a securities firm was extended. The group's 5,630,509 shares and 25.96% stake did not change. Pledged shares fell from 797,392 to 686,203.

In the company's terms

SAMIL PHARMACEUTICAL has 21,691,811 voting shares in issue. Pledged shares fell from 3.68% to 3.16% of the total. The remaining lenders are two securities firms and a bank. Interest rates range from 5.4% to 6.9%, with a collateral maintenance ratio of 150%.

What changes for shareholders

The earliest loan matures on October 26, 2026. The others end between January 4 and 11, 2027. The stated purpose is to influence management.

Comments

No comments yet

Comments from shareholders will appear here.